Cyclosporin nanosphere formulation for ophthalmic administration

Area of Science:

• Ophthalmology
• Nanotechnology
• Pharmaceutics

Background:

• Cyclosporin A (CsA) is a key anti-inflammatory agent for dry eye disease.
• Current ophthalmic emulsion formulations (e.g., RESTASIS®) can cause local toxicity and irritation.
• Improving CsA efficacy and reducing ocular side effects is clinically important.

Purpose of the Study:

• To develop and evaluate a novel CsA nanosphere (CsA-NS) formulation.
• To enhance therapeutic efficacy while minimizing ocular irritation.
• To compare CsA-NS with the marketed ophthalmic emulsion.

Main Methods:

• CsA-NS formulation prepared as a pre-concentrate solution.
• Characterization of CsA-NS for particle size, pH, and osmolarity for ophthalmic suitability.
• Evaluation of ocular irritation and CsA penetration in rabbit eyes.

Main Results:

• The developed CsA-NS formulation exhibited reduced ocular irritation in rabbit models.
• CsA penetration into rabbit eyes was comparable to the marketed emulsion formulation.
• The nanosphere formulation demonstrated suitable physicochemical properties for ophthalmic administration.

Conclusions:

• The proposed CsA-NS formulation offers a promising alternative to existing treatments for dry eye disease.
• CsA-NS formulation achieves comparable drug penetration with significantly less ocular irritation.
• Nanoparticle technology can enhance the safety profile of ophthalmic drugs like CsA.